London, 24 April 2024 - Real estate services firm Cushman & Wakefield has further strengthened its UK Healthcare team with key appointments, including hiring Peter Farnes formerly a Senior Director at CBRE.Cushman & Wakefield’s specialist UK Healthcare team provides Valuation & Advisory and transactional services in its Healthcare Markets business for national and international companies across the healthcare market. This includes care homes, seniors housing, private hospitals, medical clinics and GP practices, specialist care, childcare settings and other primary care entities.
Farnes has joined the Healthcare Markets team to bolster its market presence across the sector. Most recently at CBRE for 12 years, he has a strong track record of portfolio transactions as well as single asset acquisitions and disposals across the healthcare spectrum from care homes to medical. At Cushman & Wakefield he will be a Partner and a senior member of the transactional team, working closely with Tom Robinson - whose role as Head of Healthcare now spans both Valuation and Markets - as well as other key figures including James Hanson, Adam Lowe, David Kerr, and Amy King, Head of Seniors Housing.
Tom Robinson, Head of Healthcare at Cushman & Wakefield, said: “Peter is a strategic hire for us whose deep experience and relationships, especially in the care industry, complements the existing strengths of our transactional team. The timing is excellent as we move away from the muted investment volumes of 2023 and focus on the fundamentally-strong operator trading performance at hand. Sure enough, we’ve started to see increased activity, with portfolios on the move, a more bullish stance from global specialist investors and Private Equity coming back. This backdrop is surely the fuel needed for traditional money and new players looking to enter the market.”
Sophia Sham, a Partner who has been at Cushman & Wakefield for seven years, has been promoted to lead the Healthcare Valuation & Advisory team; one of the largest teams in the UK, providing data-led advice and commercial insight to clients ranging from regional to global players. In 2023, the team valued assets worth c.£20 billion in reported value, supporting clients from individual entrepreneurs to some of the largest specialist healthcare investors worldwide.
